These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 7056841)
1. Bone aluminum and histomorphometric features of renal osteodystrophy. Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841 [TBL] [Abstract][Full Text] [Related]
2. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018 [TBL] [Abstract][Full Text] [Related]
3. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients. Heaf JG; Nielsen LP; Mogensen NB Nephron; 1983; 35(2):103-7. PubMed ID: 6621754 [TBL] [Abstract][Full Text] [Related]
4. [A study using nondecalcified bone biopsy of the incidence and presentation forms of renal osteodystrophy]. Lorenzo Sellares V; Torres Ramírez A; Hernández Marrero D; Rodríguez Pérez J; González Posada J; Losada Cabrera M; Maceira Cruz B; Hernández Nieto L Med Clin (Barc); 1991 Apr; 96(15):561-5. PubMed ID: 2051811 [TBL] [Abstract][Full Text] [Related]
5. Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. Andress DL; Maloney NA; Coburn JW; Endres DB; Sherrard DJ J Clin Endocrinol Metab; 1987 Jul; 65(1):11-6. PubMed ID: 3584392 [TBL] [Abstract][Full Text] [Related]
6. Renal osteodystrophy--pathogenesis and treatment. Cushner HM; Adams ND Am J Med Sci; 1985 Dec; 290(6):234-45. PubMed ID: 3909812 [TBL] [Abstract][Full Text] [Related]
7. Review: Renal osteodystrophy--pathogenesis and treatment. Cushner HM; Adams ND Am J Med Sci; 1986 Apr; 291(4):264-75. PubMed ID: 3518448 [TBL] [Abstract][Full Text] [Related]
8. [Effect of strontium on bone metabolism in hemodialysis patients]. Gerstenfeld S; Hinojosa L; Serrano Arias M; Menéndez Rodríguez P; Fernández Martín JL; Marchante JM; García Alonso JI; Sanz-Medel A; Cannata Andía JB Nefrologia; 2003; 23 Suppl 2():52-6. PubMed ID: 12778855 [TBL] [Abstract][Full Text] [Related]
10. Elevated bone aluminum content in dialysis patients without osteomalacia. McCarthy JT; Kurtz SB; McCall JT Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380 [TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. Andress D; Felsenfeld AJ; Voigts A; Llach F Kidney Int; 1983 Sep; 24(3):364-70. PubMed ID: 6645210 [TBL] [Abstract][Full Text] [Related]
12. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ]. Jarava C; Armas JR; Palma A Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651 [TBL] [Abstract][Full Text] [Related]
13. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? Hodsman AB; Hood SA; Brown P; Cordy PE J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379 [TBL] [Abstract][Full Text] [Related]
14. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. Andress DL; Ott SM; Maloney NA; Sherrard DJ N Engl J Med; 1985 Feb; 312(8):468-73. PubMed ID: 3969109 [TBL] [Abstract][Full Text] [Related]
15. Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Dunstan CR; Evans RA; Hills E; Wong SY; Alfrey AC Calcif Tissue Int; 1984 Mar; 36(2):133-8. PubMed ID: 6430496 [TBL] [Abstract][Full Text] [Related]